Trial Profile
A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Iodine radioactive
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 25 Jun 2021 Status changed from recruiting to discontinued.
- 23 Mar 2021 Planned End Date changed from 23 Mar 2021 to 3 Feb 2022.
- 23 Mar 2021 Planned primary completion date changed from 31 Jan 2021 to 3 Feb 2022.